AI Article Synopsis
- * Treating DR-TB takes a long time, uses a lot of different pills, and can cause many side effects.
- * Researchers are working on new treatments, like a combination of certain medicines (BPaLM), to help fight the toughest forms of TB in India.
Article Abstract
India has a high burden of drug-resistant tuberculosis (DR-TB) cases. The management of this severe form of TB is associated with a number of issues like long treatment durations, high pill burden, and multiple adverse drug reactions. Efforts are on through various research studies and trials for finding solutions to the issues linked to the current drug regimens against drug-resistant tuberculosis. One such remarkable development is the introduction of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM)-based regimens to fight against two of the most severe forms of tuberculosis, i.e., multidrug- and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB). This editorial throws light on this newer regimen and discusses the same in the Indian context.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11445631 | PMC |
| http://dx.doi.org/10.7759/cureus.68421 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mycobacteriophages are viruses that specifically infect bacteria of the Mycobacterium genus. A substantial collection of mycobacteriophages has been isolated and characterized, offering valuable insights into their diversity and evolution. This collection also holds significant potential for therapeutic applications, particularly as an alternative to antibiotics in combating drug-resistant bacterial strains.
View Article and Find Full Text PDFDecoding the Role of Antimicrobial Peptides in the Fight against .
ACS Infect Dis
January 2025
Infectious Diseases Division, CSIR─Indian Institute of Integrative Medicine, Jammu 180001, India.
Tuberculosis (TB), a leading infectious disease caused by the pathogen , poses a significant treatment challenge due to its unique characteristics and resistance to existing drugs. The conventional treatment regimens, which are lengthy and involve multiple drugs, often result in poor patient adherence and subsequent drug resistance, particularly with multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. This highlights the urgent need for novel anti-TB therapies and new drug targets.
View Article and Find Full Text PDFIn this work, we investigated individual bacteria belonging to strains of the Beijing family with different drug sensitivity (sensitive, multi and extensive drug-resistant) by surface-enhanced Raman spectroscopy (SERS) in the fingerprint region. The latter is focused on the spectral bands, which correspond to a set of glutathione bands and DNA methylation patterns revealed due to 5-methylcytosine spectral biomarkers. It is shown that these spectral features can be correlated with drug sensitivity and DNA methylation.
View Article and Find Full Text PDFA Clinical Multicenter Trial of Recombinant Human Interferon Gamma in Tuberculosis (GAM2022) Experience with the Use of Human Recombinant Interferon Gamma in TB Practice.
Infect Disord Drug Targets
January 2025
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health, 4 Dostoyevskogo St., bldg 2, Moscow, 127473, Russia.
Background: In this article, we present the results of a multicenter clinical trial of IFN-γ in patients with drug-susceptible and drug-resistant pulmonary Tuberculosis (TB) in routine clinical practice.
Objective: This study aimed to confirm the efficacy and safety of IFN-γ administered to patients with TB.
Methods: All patients were diagnosed with TB after being tested by bacterioscopic and molecular genetic methods and had no contraindications to standard chemotherapy.
Effect of High-Fat Diets on the Pharmacokinetics of Bedaquiline Fumarate Tablet: A Trial in Healthy Chinese Participants.
Clin Pharmacol Drug Dev
January 2025
Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Bedaquiline is employed to treat multidrug-resistant and extensive drug-resistant tuberculosis by inhibiting the proton pump of adenosine triphosphate synthase in Mycobacterium tuberculosis. This study aims to investigate the effect of high-fat diets on the pharmacokinetics of bedaquiline through a single-center, open-label, randomized trial in healthy Chinese participants. Bedaquiline fumarate tablets were administered at a dosage of 100 mg under both fasted conditions and high-fat diet conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!